Morning Overview on MSN
A drug hit its goal against an aggressive lymphoma in a late-stage trial
Patients with relapsed or refractory diffuse large B-cell lymphoma, one of the fastest-growing blood cancers, gained a new ...
Key takeaways Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma. It develops when abnormal B cells rapidly accumulate in lymph nodes, causing painless swelling ...
Genmab A/S ( Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously, in the first-line (1L) treatment of patients with ...
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma. It develops when abnormal B cells rapidly accumulate in lymph nodes, causing painless swelling often in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results